Yumi Yamashita-Kanemaru

Yumi Yamashita-Kanemaru

Auto-generated profile, based on publicly available information

Yumi Yamashita-Kanemaru

Department of Pathology, University of Cambridge, Cambridge, UK

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 March 2025 in Nature
Verified
Journal Article
Open access
PDF file
JYJie Yang
Jie Yang
YYYumi Yamashita-Kanemaru
Yumi Yamashita-Kanemaru
BMBenjamin I. Morris
Benjamin I. Morris
ACAnnalisa Contursi
Annalisa Contursi
DTDaniel Trajkovski
Daniel Trajkovski
RRRahul Roychoudhuri
Rahul Roychoudhuri
Metastasis is the spread of cancer cells from primary tumours to distant organs and is the cause of 90% of cancer deaths globally1,2. Metastasizing cancer cells are uniquely vulnerable to immune attack, as they are initially deprived of the immunosuppressive microenvironment found within established tumours3. There is interest in therapeutically exploiting this immune vulnerability to prevent recurrence in patients with early cancer at risk of metastasis. Here we show that inhibitors of cyclooxygenase 1 (COX-1), including aspirin, enhance immunity to cancer metastasis by releasing T cells from suppression by platelet-derived thromboxane A2 (TXA2). TXA2 acts on T cells to trigger an immunosuppressive pathway that is dependent on the guanine exchange factor ARHGEF1, suppressing T cell receptor-driven kinase signalling, proliferation and effector functions. T cell-specific conditional deletion of Arhgef1 in mice increases T cell activation at the metastatic site, provoking immune-mediated rejection of lung and liver metastases. Consequently, restricting the availability of TXA2 using aspirin, selective COX-1 inhibitors or platelet-specific deletion of COX-1 reduces the rate of metastasis in a manner that is dependent on T cell-intrinsic expression of ARHGEF1 and signalling by TXA2 in vivo. These findings reveal a novel immunosuppressive pathway that limits T cell immunity to cancer metastasis, providing mechanistic insights into the anti-metastatic activity of aspirin and paving the way for more effective anti-metastatic immunotherapies.

19 May 2021 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
KSKazuki Sato
Kazuki Sato
YYYumi Yamashita-Kanemaru
Yumi Yamashita-Kanemaru
FAFumie Abe
Fumie Abe
RMRikito Murata
Rikito Murata
YNYuho Nakamura-Shinya
Yuho Nakamura-Shinya
KSKazuko Shibuya
Kazuko Shibuya
Significance: Immune tolerance is essential to prevent autoimmune responses, but it often needs to be limited for proper immune response. Regulatory T (Treg) cells play a crucial role in immune tolerance; however, their immune-suppressive function is restricted under inflammatory conditions. Here, we show that the activated immune receptor DNAM-1 limits Treg cell function regardless of DNAM-1–mediated intracellular signaling. We found that DNAM-1 competes with T cell immunoreceptor with Ig and ITIM domains (TIGIT) in binding to a common ligand. DNAM-1 deficiency enhances TIGIT signaling, thus resulting in the Treg cell function’s maintenance under inflammatory conditions. These results suggest that the DNAM-1 and TIGIT balance orchestrate Treg cell function for optimal immune reaction.

16 January 2026 in Nature Immunology
Verified
Journal Article
Open access
PDF file
ACAlberto G. Conti
Alberto G. Conti
AEAlexander C. Evans
Alexander C. Evans
TLTeresa von Linde
Teresa von Linde
CDChristian Deo T. Deguit
Christian Deo T. Deguit
SWSarah K. Whiteside
Sarah K. Whiteside
RRRahul Roychoudhuri
Rahul Roychoudhuri
Adoptive T cell therapies are limited by poor persistence of transferred cells. Attempts to enhance persistence have focused on genetic induction of constitutively hyperactivated but potentially oncogenic T cell states. Physiological T cell responses are maintained by quiescent stem-like/memory cells dependent upon the transcription factor BACH2. Here we show that quantitative control of BACH2 dosage regulates differentiation along the continuum of stem and effector CD8⁺ T cell states, enabling engineering of synthetic states with persistent antitumor activity. While conventional high-level overexpression of BACH2 enforces quiescence and hinders tumor control, low-dose BACH2 expression promotes persistence without compromising effector function, enhancing anticancer efficacy. Mechanistically, low-dose BACH2 partially attenuates Jun occupancy at highly AP-1-dependent genes, restraining terminal differentiation while preserving effector programs. Similarly, dose optimization enables effective deployment of quiescence factor FOXO1. Thus, quantitative control of gene payloads yields qualitative effects on outcome with implications for quiescence factor deployment in cell therapy.

9 April 2026 in Signal Transduction and Targeted Therapy
Verified
Journal Article
Open access
SCSoura Chakraborty
Soura Chakraborty
JPJhuma Pramanik
Jhuma Pramanik
GAGustavo Alviter-Raymundo
Gustavo Alviter-Raymundo
CWChristopher J. Ward
Christopher J. Ward
SSSanu K. Shaji
Sanu K. Shaji
BMBidesh Mahata
Bidesh Mahata
Tumors foster an immunosuppressive microenvironment to evade the antitumor immune response. However, the influence of intratumoral immunosuppressive steroids on tumor-infiltrating natural killer (NK) cells and their implications for effective immunotherapy has remained largely unexplored. Here, we report that the functional enrichment of glucocorticoid cortisol signaling in the lung tumor microenvironment (TME) impairs NK cell anti-tumor cytotoxicity and exacerbates hypoxic stress. Cancer-associated fibroblasts (CAFs) and macrophages convert inactive cortisone to active cortisol, while T cells, fibroblasts, myeloid cells, macrophages, and cancer cells contribute to de novo steroid biosynthesis, collectively establishing a steroid-rich niche. Pharmacological inhibition of the glucocorticoid receptor (GR) in vivo alleviates cortisol-mediated immune suppression, resulting in reduced tumor growth and enhanced cytotoxicity of tumor-infiltrating NK cells. To overcome the cortisol-induced dysfunction of solid tumor targeting immunotherapy, we engineered chimeric antigen receptor (CAR) -NK cells specific to the C arcino e mbryonic a ntigen-related c ell a dhesion m olecule 5 (CEACAM5) (highly expressed in lung tumors) and rendered them cortisol-resistant by genetic deletion of the cortisol receptor gene NR3C1 . In cortisol-rich niches, cortisol-resistant CAR-NK cells sustained antitumor cytotoxicity. Mechanistically, NR3C1 deletion relieved cortisol-mediated suppression of PI3K-AKT-NF-κB signaling, restored anti-tumor activity, and markedly reduced hypoxic stress. In lung metastasis models, cortisol-resistant CAR-NK cells achieved superior tumor control and significantly reduced tumor burden compared with conventional CAR-NK cells. Together, these findings identify local cortisol signaling as a critical barrier to solid tumor immunotherapy and establish cortisol-resistant CAR-NK cells as a promising strategy for targeting steroidogenic solid tumors, which can be combined with therapeutic glucocorticoids.

3 September 2026 in Science
Verified
Journal Article
Closed access
AWAlexander J. Wesolowski
Alexander J. Wesolowski
APArdon M. Pillay
Ardon M. Pillay
PVPanagiota Vardaka
Panagiota Vardaka
RNRabab Nasrallah
Rabab Nasrallah
RGRandy Greaves
Randy Greaves
RRRahul Roychoudhuri
Rahul Roychoudhuri
Reactive oxygen species (ROS) promote genomic instability and fuel oncogenic signaling in cancer, but antioxidant therapies have so far failed to improve, or worsen, cancer outcomes. Emerging data suggest that T cells depend on ROS for signal transduction. In this study, we show that tumors exploit this dependency, releasing antioxidant enzymes into the tumor environment to suppress T cell–mediated antitumor immunity. The interstitial fluid of tumors possesses potent antioxidant activity, associated with enrichment of the antioxidant enzyme peroxiredoxin 1 (PRDX1). Extracellular PRDX1 deprives T cells of ROS, preventing oxidative inactivation of phosphatases required for T cell receptor–driven kinase signaling and effector function. Prdx1 is up-regulated upon cancer immunoediting, and loss of PRDX1 within tumors enhances antitumor immunity and immunotherapy responses. These findings define a redox-dependent mechanism of tumor immunosuppression that is potentially amenable to therapeutic intervention.

16 October 2026 in Science Advances
Verified
Journal Article
Closed access
JPJhuma Pramanik
Jhuma Pramanik
QZQiuchen Zhao
Qiuchen Zhao
SCSoura Chakraborty
Soura Chakraborty
YYYumi Yamashita-Kanemaru
Yumi Yamashita-Kanemaru
HHHosni Hussein
Hosni Hussein
BMBidesh Mahata
Bidesh Mahata
Steroid hormones are well-known regulators of mast cell function, but whether mast cells themselves produce steroids de novo and influences their effector function has remained unknown. Here, we show that mast cells constitutively express the steroidogenic enzyme cytochrome P450 family 11 subfamily A member 1 (Cyp11a1) and produce pregnenolone. Cyp11a1 expression was detected across tissue-resident mast cells from multiple organs, was conserved in human mast cells, and was enhanced by interleukin-3 signaling and after activation. We identified Cyp11a1 as a Gata2-dependent, superenhancer-associated mast cell gene, placing steroidogenesis within the core mast cell transcriptional program. Loss of Cyp11a1 altered transcriptomic and proteomic programs in mast cells, with effects on pathways linked to cell growth, immune signaling, and effector function. Functionally, Cyp11a1-deficient mast cells showed increased degranulation in response to both immunoglobulin E (IgE)–dependent and IgE-independent stimulation. In vivo, loss of Cyp11a1 reduced mast cell abundance in several tissues but exacerbated passive cutaneous anaphylaxis. These findings identify cell-intrinsic steroidogenesis as a regulatory pathway that restrains mast cell activation and anaphylactic responses.